PORTSIDE
Phase 2 Terminated
38 enrolled
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase 1 Terminated
79 enrolled 24 charts
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Phase 2 Terminated
5 enrolled 13 charts
ATLAS
Phase 2 Terminated
5 enrolled
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
Phase 1/2 Terminated
23 enrolled
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
Phase 1 Terminated
67 enrolled
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
Phase 2 Terminated
15 enrolled
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Phase 1/2 Terminated
6 enrolled 11 charts
CPIT001
Phase 1/2 Terminated
46 enrolled 13 charts
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
Phase 2 Terminated
8 enrolled 11 charts
GVAX Plus Checkpoint Blockade in Neuroblastoma
Phase 1 Terminated
19 enrolled
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Phase 1 Terminated
8 enrolled
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
Phase 1 Terminated
6 enrolled
PRIMO
Phase 1 Terminated
25 enrolled
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
Phase 2 Terminated
4 enrolled 11 charts
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
Phase 2 Terminated
12 enrolled 16 charts
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
Phase 1 Terminated
11 enrolled
INFLUENCE
Phase 2 Terminated
19 enrolled
QUAD01
Phase 1/2 Terminated
2 enrolled 12 charts
Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
Phase 1 Terminated
1 enrolled
A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
Phase 2 Terminated
14 enrolled 12 charts
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
Phase 1 Terminated
9 enrolled
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
Phase 2 Terminated
1 enrolled
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
Phase 1 Terminated
22 enrolled 14 charts
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
NIMBLe
Phase 2 Terminated
4 enrolled 4 charts
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
Phase 1 Terminated
2 enrolled 14 charts
Ipilimumab and Local Radiation for Selected Solid Tumors
Phase 1 Terminated
3 enrolled 5 charts
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Phase 2 Terminated
9 enrolled 17 charts
PROCLIVITY02
Phase 4 Terminated
29 enrolled 9 charts
FLX475 in Combination With Ipilimumab in Advanced Melanoma
Phase 2 Terminated
6 enrolled 10 charts
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
Phase 2 Terminated
30 enrolled 12 charts
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
Phase 1 Terminated
6 enrolled
Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
Phase 1 Terminated
6 enrolled
Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
Phase 1/2 Terminated
15 enrolled 9 charts
Immunotherapy Study for Patients With Stage IV Melanoma
Phase 2 Terminated
47 enrolled 16 charts
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
Phase 2 Terminated
14 enrolled 12 charts
Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
Phase 1/2 Terminated
3 enrolled 5 charts
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
Phase 1/2 Terminated
80 enrolled 33 charts
CheckMate 76U
Phase 1 Terminated
21 enrolled
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
Phase 1/2 Terminated
19 enrolled 12 charts
Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Phase 2 Terminated
5 enrolled 10 charts
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
Phase 2 Terminated
5 enrolled 11 charts
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Phase 3 Terminated
481 enrolled 22 charts
A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer
Phase 2 Terminated
28 enrolled 16 charts
Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors
Phase 2 Terminated
11 enrolled 9 charts
A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma
Phase 2 Terminated
6 enrolled 8 charts
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Phase 1 Terminated
8 enrolled 16 charts
Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma
Phase 1 Terminated
5 enrolled 12 charts
Neoadjuvant Immunotherapy in Brain Metastases
Phase 2 Terminated
1 enrolled 7 charts